Brief: Journey Medical Corporation Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi™ (Dfd-29) To Treat Rosacea
05/03/2025 22:23
March 5 (Reuters) - Journey Medical Corp DERM.O: JOURNEY MEDICAL CORPORATION ANNOUNCES PUBLICATION IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION - DERMATOLOGY OF THE PHASE 3 CLINICAL TRIAL RESULTS OF EMROSI™ (DFD-29) TO TREAT ROSACEA Source text: ID:nGNXbJ7zqf Further company coverage: DERM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi